EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, SRPT: Sarepta Therapeutics

10 Nov 25 18:23
LAST:

17.27

CHANGE:
 0.36		OPEN:
18.13		HIGH:
18.13		ASK:
32.50		VOLUME:
3.44M
CHG(%):
2.04		PREV:
17.63		LOW:
17.26		BID:
10.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
10 Nov 2518.1318.1317.2617.273.45M
07 Nov 2517.7717.9516.5517.634.19M
06 Nov 2518.6418.7517.4117.646.57M
05 Nov 2516.5918.8016.5818.6711.14M
04 Nov 2515.2417.7515.0816.2023.91M
03 Nov 2524.2724.5522.6724.4515.57M
31 Oct 2523.4224.4823.0224.014.51M
30 Oct 2523.2223.3922.7923.253.42M
29 Oct 2524.0224.0923.1523.453.72M
28 Oct 2523.4824.4023.2724.223.44M

COMPANY PROFILE

Name:Sarepta Therapeutics
About:Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:215 First Street, Cambridge, MA, United States, 02142
Website:https://www.sarepta.com
CUSIP:037184108
CIK:0000873303
ISIN:US8036071004
FIGI:BBG000BCJ161
LEI:549300IKDPIED8J8IG21

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:19.98 
Forward P/E:2.10 
PEG Ratio:0.01 
Price to Sales:1.01 
Price to Book:1.73 
Profit Margin:-0.02 
Operating Margin:0.19 
Return on Assets:0.00 
Return on Equity:-0.05 
EPS Ratio:-0.68 
Revenue:2.482B 
EBITDA:324.73M 
Shares:104.67M 
Market Cap:1.808B 

TECHNICAL INDICATORS

MA5:17.481.2%
MA10:20.6819.7%
MA20:21.6725.5%
MA50:20.2817.5%
MA100:19.0210.2%
MA200:43.74153.2%
STO9:12.81 
STO14:12.81 
RSI14:33.19 
WPR14:-87.03 
MTM14:-5.20
ROC14:-0.23 
ATR:1.96 
Week High:24.5542.2%
Week Low:15.0814.5%
Month High:24.5542.2%
Month Low:15.08153.2%
Year High:138.81703.8%
Year Low:10.4265.8%
Volatility:5.91 

RECENT SPLITS

Date Ratio
12 Jul 20121-6